Title
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
Clinical Phase I/II Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
Phase
Phase 1/Phase 2Lead Sponsor
MedacStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Brain NeoplasmIntervention/Treatment
aminolevulinic acid ...Study Participants
21This study is planned to detect a dose-efficacy relationship between the chosen dose levels of MC506/1 and the extent and quality of fluorescence in the tumour core in patients with newly diagnosed malignant glioma.
Inclusion Criteria: Radiological suspicion of a malignant glioma with distinct ring- or garland shaped, contrast agent-enhancing tumour structures and a core area of reduced intensity in the MRI (tumour necrosis) Indication for surgical tumour resection First operation of the tumour, no other tumour-specific pre-treatment Karnofsky Performance Scale 70% Patient's written informed consent Age 18-75 years Exclusion Criteria: Porphyria, hypersensitivity to porphyrins Renal insufficiency: Creatinine > 2.0 mg/dl Hepatic insufficiency: Bilirubin > 3 mg/dl Quick test < 60 % GT > 100 U/I Other known malignancy (except basaliomas) Women: Existing/planned pregnancy (to be checked by a pregnancy test if of child-bearing age)/lactation or inadequate contraception (hormone cycle regulation pill or condom) Men: Inadequate contraception (condom) Dementia or mental condition making it impossible to understand the therapy and therefore prohibiting written consent Simultaneous participation or participation in another clinical trial in the preceding 30 days